E-resources
Peer reviewed
-
Bell, Ian M; Gallicchio, Steven N; Abrams, Marc; Beshore, Douglas C; Buser, Carolyn A; Culberson, J. Christopher; Davide, Joseph; Ellis-Hutchings, Michelle; Fernandes, Christine; Gibbs, Jackson B; Graham, Samuel L; Hartman, George D; Heimbrook, David C; Homnick, Carl F; Huff, Joel R; Kassahun, Kelem; Koblan, Kenneth S; Kohl, Nancy E; Lobell, Robert B; Lynch, Joseph J; Miller, Patricia A; Omer, Charles A; Rodrigues, A. David; Walsh, Eileen S; Williams, Theresa M
Journal of medicinal chemistry, 08/2001, Volume: 44, Issue: 18Journal Article
The synthesis, structure−activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-aminopyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model.
